ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity

Journal: Nature

Published: 2020-02-19

DOI: 10.1038/s41586-020-2015-4

Affiliations: 18

Authors: 21

Go to article
Institutions Share
Parker Institute for Cancer Immunotherapy, United States of America (USA) 0.14
Department of Surgery, MSKCC, United States of America (USA) 0.12
David M. Rubenstein Center for Pancreatic Cancer Research, MSKCC, United States of America (USA) 0.12
Department of Pathology, MSKCC, United States of America (USA) 0.10
Lustgarten Foundation Pancreatic Cancer Research Laboratory, CSHL, United States of America (USA) 0.07
Cold Spring Harbor Laboratory (CSHL), United States of America (USA) 0.07
BMS Princeton, United States of America (USA) 0.05
Department of Epidemiology and Biostatistics, MSKCC, United States of America (USA) 0.05
Dartmouth-Hitchcock Norris Cotton Cancer Center, United States of America (USA) 0.05
Department of Surgery, Penn, United States of America (USA) 0.05
Ludwig Center at MSK, United States of America (USA) 0.04
Swim Across America Laboratory at MSKCC, United States of America (USA) 0.04
Weill Cornell Medicine (WCM), Cornell University, United States of America (USA) 0.03
Ansary Stem Cell Institute, Cornell University, United States of America (USA) 0.02
Division of Regenerative Medicine, Cornell University, United States of America (USA) 0.02
Department of Medicine, MSKCC, United States of America (USA) 0.02
Human Oncology and Pathogenesis Program (HOPP), MSKCC, United States of America (USA) 0.01

Return